Research programme: hepatitis C virus NS3/4A protein inhibitors - AbbVie/Enanta
Alternative Names: EA-058; EA-063; EA-084; HCV serine protease inhibitor programme - Abbott/EnantaLatest Information Update: 04 Nov 2017
At a glance
- Originator Enanta Pharmaceuticals
- Developer AbbVie; Enanta Pharmaceuticals
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA (PO)
- 23 Mar 2010 Development in this programme is ongoing
- 26 Apr 2009 Antimicrobial and pharmacokinetics data from preclinical studies in Hepatitis C presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)